About Omnia Biologics
Omnia Biologics is a company based in Rockville (United States) founded in 2001 was acquired by Vigene Biosciences in November 2016. Omnia Biologics has raised $25.4 million across 2 funding rounds from investors including Vigene Biosciences and Medipost. Omnia Biologics offers products and services including Process Development, Analytical Development, GMP Manufacturing, and Commercial Manufacturing. Omnia Biologics operates in a competitive market with competitors including KBI Biopharma, EirGenix, Aldevron, Arranta Bio and Ovagen, among others.
- Headquarter Rockville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Omniabio Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$25.4 M (USD)
in 2 rounds
-
Latest Funding Round
$23.9 M (USD), Series B
May 24, 2022
-
Investors
Vigene Biosciences
& 1 more
-
Employee Count
Not available
-
Acquired by
Vigene Biosciences
(Nov 29, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Omnia Biologics
Omnia Biologics offers a comprehensive portfolio of products and services, including Process Development, Analytical Development, GMP Manufacturing, and Commercial Manufacturing.
Optimizes processes for cell and gene therapy production.
Develops assays for quality control in therapies.
Delivers compliant manufacturing for cell therapies.
Supports large-scale therapy production and delivery.
People of Omnia Biologics
Unlock access to complete
Funding Insights of Omnia Biologics
Omnia Biologics has successfully raised a total of $25.4M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $23.9 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Omnia Biologics
Omnia Biologics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Vigene Biosciences and Medipost.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Research reagents for drug discovery and functional genomics are developed.
|
Locked | Locked | Locked |
Investor details for Omnia Biologics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Omnia Biologics
Investment portfolio details for Omnia Biologics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Omnia Biologics
Detailed financials for Omnia Biologics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Omnia Biologics Comparisons
Peer comparison for Omnia Biologics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Omnia Biologics
Omnia Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KBI Biopharma, EirGenix, Aldevron, Arranta Bio and Ovagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of protein formulation, process & cell line development, and cGMP services
|
|
| Locked | Locked | Locked |
Biologics development and manufacturing services are offered by EirGenix.
|
|
| Locked | Locked | Locked |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| Locked | Locked | Locked |
Developer of therapeutics for microbiome based diseases
|
|
| Locked | Locked | Locked |
Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services
|
|
| Locked | Locked | Locked |
Vaccines and biologics are developed and manufactured by IDT Biologika.
|
Detailed competitors of Omnia Biologics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Omnia Biologics
Complete news archive for Omnia Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Omnia Biologics
Omnia Biologics was founded in 2001 and raised its 1st funding round 5 years after it was founded.
Omnia Biologics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Omnia Biologics is a funded company, having raised a total of $25.4M across 2 funding rounds to date.
Omnia Biologics was founded in 2001 in Rockville, United States, focusing on the biologics sector. Non-GMP and GMP facilities were utilized for process development from preclinical stages through Phase III manufacturing. Expertise encompassed adenovirus, lentivirus, retrovirus, AAV, VLP, and other viral platforms. Services included manufacturing, process development, cell and virus banking, and aseptic filling. Orders are no longer accepted, with diversions directed to Vigene Biosciences.
Omnia Biologics's top competitors include KBI Biopharma, Aldevron and Ovagen.
Omnia Biologics offers Process Development, Analytical Development, GMP Manufacturing, and Commercial Manufacturing.
Omnia Biologics has 2 investors. Key investors include Vigene Biosciences, and Medipost.